Extended Data Fig. 6: Mutation frequency profiles of treatment naïve CRCs from the TCGA Pan-Cancer study vs. the KRAS hotspot mutations identified in ref. 28.
From: Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer
The TCGA profile has been adjusted to only consider KRAS mutations that were assessed in the CORRECT trial.
